Lancet Diabetes & Endocrinology

Papers
(The H4-Index of Lancet Diabetes & Endocrinology is 82. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)
ArticleCitations
Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: a whole-population study667
Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: a population-based cohort study638
COVID-19 in people with diabetes: understanding the reasons for worse outcomes619
Epidemiology and determinants of obesity in China610
Practical recommendations for the management of diabetes in patients with COVID-19600
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials427
Endocrine-disrupting chemicals: implications for human health354
Associations between body-mass index and COVID-19 severity in 6·9 million people in England: a prospective, community-based, cohort study331
Causes, consequences, and treatment of metabolically unhealthy fat distribution315
Consensus on diagnosis and management of Cushing's disease: a guideline update298
Cerebral microvascular complications of type 2 diabetes: stroke, cognitive dysfunction, and depression282
Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial282
Risks and burdens of incident diabetes in long COVID: a cohort study280
Screening for diabetic retinopathy: new perspectives and challenges273
Vitamin D supplementation to prevent acute respiratory infections: a systematic review and meta-analysis of aggregate data from randomised controlled trials264
Thyroid cancer incidence trends by histology in 25 countries: a population-based study240
Global incidence, prevalence, and mortality of type 1 diabetes in 2021 with projection to 2040: a modelling study230
Risks of and risk factors for COVID-19 disease in people with diabetes: a cohort study of the total population of Scotland229
Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials226
A global view of the interplay between non-alcoholic fatty liver disease and diabetes224
Obesity in children and adolescents: epidemiology, causes, assessment, and management214
SARS-CoV-2-related atypical thyroiditis199
Gestational diabetes: opportunities for improving maternal and child health197
Global trends in thyroid cancer incidence and the impact of overdiagnosis192
Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study189
Prevalence of obesity among adult inpatients with COVID-19 in France187
Polycystic ovary syndrome183
Type 2 diabetes and cognitive dysfunction—towards effective management of both comorbidities183
Type 1 diabetes—early life origins and changing epidemiology181
Effect of intensive lifestyle intervention on bodyweight and glycaemia in early type 2 diabetes (DIADEM-I): an open-label, parallel-group, randomised controlled trial178
Association between high serum total cortisol concentrations and mortality from COVID-19174
Vitamin-D and COVID-19: do deficient risk a poorer outcome?170
The epidemiological landscape of thyroid cancer worldwide: GLOBOCAN estimates for incidence and mortality rates in 2020167
Trends in predominant causes of death in individuals with and without diabetes in England from 2001 to 2018: an epidemiological analysis of linked primary care records162
Health policy and public health implications of obesity in China160
Testosterone treatment to prevent or revert type 2 diabetes in men enrolled in a lifestyle programme (T4DM): a randomised, double-blind, placebo-controlled, 2-year, phase 3b trial157
Body-mass index and risk of obesity-related complex multimorbidity: an observational multicohort study156
Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial155
Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomi155
Ethnicity-specific BMI cutoffs for obesity based on type 2 diabetes risk in England: a population-based cohort study150
Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group150
COVID-19 and metabolic disease: mechanisms and clinical management148
Vitamin D for COVID-19: a case to answer?143
Characteristics and outcomes of pregnant women with type 1 or type 2 diabetes: a 5-year national population-based cohort study140
Endocrine-disrupting chemicals: economic, regulatory, and policy implications140
Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial138
RETRACTED: Estimating dose-response relationships for vitamin D with coronary heart disease, stroke, and all-cause mortality: observational and Mendelian randomisation analyses136
Epidemiology of adrenal tumours in Olmsted County, Minnesota, USA: a population-based cohort study133
Prescription of glucose-lowering therapies and risk of COVID-19 mortality in people with type 2 diabetes: a nationwide observational study in England132
Continuous glucose monitoring and metrics for clinical trials: an international consensus statement130
Towards unified and impactful policies to reduce ultra-processed food consumption and promote healthier eating129
Bariatric and metabolic surgery during and after the COVID-19 pandemic: DSS recommendations for management of surgical candidates and postoperative patients and prioritisation of access to surgery126
Urine steroid metabolomics for the differential diagnosis of adrenal incidentalomas in the EURINE-ACT study: a prospective test validation study123
Central nervous pathways of insulin action in the control of metabolism and food intake122
Association of maternal thyroid function with birthweight: a systematic review and individual-participant data meta-analysis122
Bone fragility in diabetes: novel concepts and clinical implications119
Management of diabetes and hyperglycaemia in the hospital119
Treatment of type 2 diabetes: challenges, hopes, and anticipated successes117
Treatment-related changes in bone mineral density as a surrogate biomarker for fracture risk reduction: meta-regression analyses of individual patient data from multiple randomised controlled trials112
Inadequate β-cell mass is essential for the pathogenesis of type 2 diabetes107
Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase106
Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial105
Clinical management and treatment of obesity in China104
Dose-response, efficacy, and safety of oral semaglutide monotherapy in Japanese patients with type 2 diabetes (PIONEER 9): a 52-week, phase 2/3a, randomised, controlled trial100
Guideline recommendations and the positioning of newer drugs in type 2 diabetes care100
Metformin in women with type 2 diabetes in pregnancy (MiTy): a multicentre, international, randomised, placebo-controlled trial99
Diagnosis and treatment of primary aldosteronism99
Glucose-lowering drugs or strategies, atherosclerotic cardiovascular events, and heart failure in people with or at risk of type 2 diabetes: an updated systematic review and meta-analysis of randomise98
Diabetes, metabolic disease, and telomere length96
Association of glucose-lowering medications with cardiovascular outcomes: an umbrella review and evidence map95
Nutritional intake and bone health95
Intake and metabolism of omega-3 and omega-6 polyunsaturated fatty acids: nutritional implications for cardiometabolic diseases93
Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel91
Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 87
Safety and efficacy of oral semaglutide versus dulaglutide in Japanese patients with type 2 diabetes (PIONEER 10): an open-label, randomised, active-controlled, phase 3a trial87
Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multic87
Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial86
Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial85
Global patterns and trends in incidence and mortality of thyroid cancer in children and adolescents: a population-based study85
Anti-interleukin-21 antibody and liraglutide for the preservation of β-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial84
Trends in the incidence of diagnosed diabetes: a multicountry analysis of aggregate data from 22 million diagnoses in high-income and middle-income settings82
Effects of once-weekly subcutaneous semaglutide on kidney function and safety in patients with type 2 diabetes: a post-hoc analysis of the SUSTAIN 1–7 randomised controlled trials82
0.054762125015259